Bone Loss/Osteoporosis

HIV Treatment Interruption Associated with Reduced Bone Loss in SMART Trial

People who stopped antiretroviral therapy (ART) in the SMART trial had less bone loss and lower levels of bone metabolism biomarkers than people who remained on continuous treatment, according to a report in the January 8, 2013, advance edition of Journal of Bone Mineral Research.

alt

Read more:

Study Finds Increased Fractures in First 2 Years after Starting Antiretroviral Treatment

HIV positive individuals appear to have significantly increased risk of bone fractures during the first 2 years after beginning antiretroviral therapy (ART), but the risk returned to baseline levels thereafter, according to a study published in the November 2012 issue of the journal AIDS.

alt

Read more:

ICAAC 2012: Bone Loss Is Common in French HIV Cohort, Linked to Older Age and Lower Weight

As many as half of people with HIV may have some degree of bone loss -- and up to 20% may experience fractures -- but no other significant risk factors could be determined other than older age and low body mass index, researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this month in San Francisco. alt

Read more:

ICAAC 2012: Simplified Abacavir/Atazanavir Combo Keeps HIV Suppressed, May Help Bones

Substituting abacavir/lamivudine (the drugs in Epzicom) for tenofovir/emtricitabine (the drugs in Truvada) and dropping the ritonavir (Norvir) booster with atazanavir (Reyataz) maintains undetectable HIV viral load and improves biomarkers of bone loss, researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) last month in San Francisco. alt

Read more:

AIDS 2012: HIV+ Men Prone to Bone Fractures at Earlier Age

HIV positive men in the long-running MACS cohort appeared to sustain osteoporosis-related bone fractures at an earlier age than HIV negative men, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC. A related study found several factors that predict greater risk of fractures, including use of protease inhibitors and proton pump inhibitors. alt

Read more: